Nuclear factor-κB inhibitors as sensitizers to anticancer drugs

By Chikashi Nakanishi, Masakazu Toi. Nature Reviews. Cancer, 2005

716 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Discovery and Development of the G-rich Oligonucleotide AS1411 as a Novel Treatment for Cancer (2009, background): “This protein was of interest to us because of its essential role in canonical NF-κB signaling, a pathway which is closely linked to the chemoresistance of cancer cells [167] and which had previously been reported to be inhibited by other types of G-rich oligonucleotides [33].”
Is NF-κB a good target for cancer therapy? Hopes and pitfalls (2009, background): “As tumour cells often use NF-κB to achieve resistance to anticancer drugs and radiation therapy, inhibition of NF-κB activation seems to be a promising option to improve the efficacy of conventional anticancer therapie”
Strategies to improve radiotherapy with targeted drugs (2011, background): “Small-molecule inhibitors developed against proteins in this pathway have been shown to radiosensitize cultured human cancer cell”
Oncogenic PI3K deregulates transcription and translation (2005, background): “In human cancer cells, NFκB positively regulates cell survival, proliferation, chemoresistance, angiogenesis, cellular invasion and oncogenesi”